Chalkias, Spyros
Eder, Frank
Essink, Brandon
Khetan, Shishir
Nestorova, Biliana
Feng, Jing
Chen, Xing http://orcid.org/0000-0002-6740-9535
Chang, Ying
Zhou, Honghong
Montefiori, David
Edwards, Darin K. http://orcid.org/0000-0002-2065-2941
Girard, Bethany
Pajon, Rolando http://orcid.org/0000-0002-5155-5079
Dutko, Frank J.
Leav, Brett
Walsh, Stephen R. http://orcid.org/0000-0002-0817-9370
Baden, Lindsey R.
Miller, Jacqueline M.
Das, Rituparna
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Article History
Received: 15 April 2022
Accepted: 1 September 2022
First Online: 6 October 2022
Competing interests
: D.M. reports funding from Moderna, Inc. to perform the pseudovirus neutralization assays. S.R.W. reports funding from Moderna, Inc., Janssen/Johnson & Johnson and Sanofi for clinical trials. L.R.B. is a co-primary principal investigator of the COVE trial, funded by the National Institute of Allergy and Infectious Diseases and conducted in conjunction with Moderna, Inc. S.C., B.N., J.F., X.C., Y.C., H.Z., D.K.E., R.P., B.L., J.M.M. and R.D. are employees of Moderna, Inc. and may hold stock/stock options in the company. F.D. is a consultant for Moderna, Inc. B.E. and F.E. report no conflicts of interest.